Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST) "CATALIST"


Phase 2 Results

Summary of Purpose

Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and damages brain cells. The clot, or thrombus, is made up of platelets and fibrin. The medicine alteplase, also known as tPA , is the standard drug used to treat patients with acute ischemic stroke. tPA attacks the fibrin portion of the blood clot. While intravenous (iv) tPA alone is effective in treating the fibrin part of...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 27 December 2012.

1 May 2003 23 May 2003 1 Dec 2009 1 Jul 2011 1 Dec 2012 27 Dec 2012
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Non-Randomized
  • Masking: Open Label
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Single Group Assignment


  • Lisa Davis, RN, MSN, CCRC Senior Nurse Specialist NIH/NINDS Section on Stroke Diagnostics and Therapeutics 10 Center Drive, MSC 1063 Building 10, Room B1D733 Bethesda, MD 20892-1063 Telephone: 301-435-7659 Fax: 301-480-0413 Email: